THE RISK OF DEVELOPING ASTHMA IN CHILDREN, WHO HAVE HAD RESPIRATORY SYNCYTIAL INFECTION IN INFANCY
https://doi.org/10.52485/19986173_2023_2_141
Abstract
The causes of the formation of bronchial asthma (BA) are the object of most research to this day. It is known that past acute respiratory diseases, having a certain seasonality, can cause periodic occurrence of airway obstruction, with the further formation of BA, which leads to an increase in requests for medical help and a deterioration in the quality of life.
The scientific review is devoted to summarizing the results of modern research on the long-term consequences of respiratory syncytial virus infection (RSVI) transferred at an early age. The databases PubMED, RSCI were used. The search keywords were: respiratory syncytial virus infection, early childhood, broncho-obstructive syndrome, bronchial asthma, palivizumab, nirsevimab, motavizumab. Found 42187 publications for search words over the past 5 years. Most publications note a pathogenetic relationship between RSVI and BA. The authors also note the need for immunization of infants with monoclonal antibodies to prevent the development of complications.
About the Authors
A. S. Medvedeva
Chita State Medical Academy
Russian Federation
Russian Federation
39a Gorky Street, Chita, 672000
V. A. Shcherbak
Chita State Medical Academy
Russian Federation
Russian Federation
39a Gorky Street, Chita, 672000
References
1. Potapova N.L. Life-threatening bronchial asthma in children: from predictors to prognosis. Russian Bulletin of Perinatology and Pediatrics. 2021. 66(2). 29-34. – DOI 10.21508/1027-40652021-66-2-29-34. in Russian.
2. Baraldi E., Checcucci Lisi G., Costantino C., Heinrichs J.H., Manzoni P., Riccò M., Roberts M., Vassilouthis N. RSV disease in infants and young children: Can we see a brighter future? Hum Vaccin Immunother. 2022. 18(4). 2079322. doi: 10.1080/21645515.2022.2079322.
3. Davydova I.V. Long-term consequences of respiratory syncytial viral infection in early childhood. Pediatrics, journal named after G.N. Speransky. 2018. 97 (6). 156–161. DOI: 10.24110/0031403X-2018-97-6-156-161. in Russian.
4. Cohen C., Zar H.J. Deaths from RSV in young infants-the hidden community burden. Lancet Glob Health. 2022. 10(2). e169-e170. doi: 10.1016/S2214-109X(21)00558-1.
5. Laudanno S.L., Sánchez Yanotti C.I., Polack F.P. RSV Lower Respiratory Tract Illness in Infants of Low- and Middle-income Countries. Acta Med Acad. 2020. 49(2). 191-197. doi: 10.5644/ama2006-124.297.
6. Azzari C., Baraldi E., Bonanni P., Bozzola E., Coscia A., Lanari M., Manzoni P., Mazzone T., Sandri F., Checcucci Lisi G., Parisi S., Piacentini G., Mosca F. Epidemiology and prevention of respiratory syncytial virus infections in children in Italy. Ital J Pediatr. 2021. 47(1). 198. doi: 10.1186/s13052-021-01148-8.
7. Fan P., Liu Z., Zheng M., Chen M., Xu Y., Zhao D. Respiratory syncytial virus nonstructural protein 1 breaks immune tolerance in mice by downregulating Tregs through TSLP- OX40/OX40L-mTOR axis. Mol Immunol. 2021. 138. 20-30. doi: 10.1016/j.molimm.2021.07.019.
8. Matsuda S., Kato M., Koike T., Kama Y., Suzuki K., Enseki M., Tabata H., Hirai K., Yamada Y., Mochizuki H. Differences in Virus Detection and Cytokine Profiles between First Wheeze and Childhood Asthma. Tokai J Exp Clin Med. 2020. 45(1). 10-17.
9. Barr R., Green C.A., Sande C.J, Drysdale S.B. Respiratory syncytial virus: diagnosis, prevention and management. Ther Adv Infect Dis. 2019. 29(6). 2049936119865798. doi: 10.1177/2049936119865798.
10. Raita Y., Pérez-Losada M., Freishtat J., Harmon B., Mansbach J.M., Piedra P.A., Zhu Zh., Camargo C.A., Hasegawa K. Integrated omics endotyping of infants with respiratory syncytial virus bronchiolitis and risk of childhood asthma. Nat Commun. 2021. 12(1). 3601. doi: 10.1038/s41467-021-23859-6.
11. Samsygina G.A. Differential diagnosis of the causes of frequent acute respiratory infections in children. Pediatrics. Journal named after G.N. Speransky. 98 (1). 193-200. DOI 10.24110/0031403X-2019-98-1-193-200. in Russian.
12. Wohlford E.M., Borrell L.N., Elhawary J.R., Plotkin B., Oh S.S., Nuckton T.J., Eng C., Salazar S., LeNoir M.A., Meade K., Farber H.J., Serebrisky D., Brigino-Buenaventura E., RodriguezCintron W., Kumar R., Thyne S., Seibold M.A., Rodríguez-Santana J.R., Burchard E.G. Differential asthma odds following respiratory infection in children from three minority populations. PLoS One. 2020. 15(5). e0231782. doi: 10.1371/journal.pone.0231782.e.Collection 2020.
13. Jalink M.B., Langley M., Dodds L., Andreou P. Severe Respiratory Syncytial Virus Infection in Preterm Infants and Later Onset of Asthma. Pediatr Infect Dis J. 2019.38(11). 1121-1125. doi: 10.1097/INF.0000000000002432.
14. Kondratieva E.I., Nikonova V.S. Immunization of patients with cystic fibrosis. Pediatrics. Journal named after G.N. Speransky. 2014. 93(4). 94-106. in Russian.
15. Krsheminskaya I.V., Kravchuk D.A., Ovsyannikov D.Yu., Bolibok A.M., Pavlova E.S., Larina V.N. Influence of immunoprophylaxis of respiratory syncytial virus infection with palivizumab on the development of bronchial asthma in children with bronchopulmonary dysplasia. Pediatrics, journal named after G.N. Speransky. 2020. 99(2). 63-68. DOI: 10.24110/0031-403X-2020-99-263-68. in Russian.
16. Igde M., Kabasakal H., Ozturk O., Karatekin G., Aygun C. Palivizumab prophylaxis, respiratory syncytial virus and subsequent development of asthma. Minerva Pediatr. 2018. 70(3). 252-259. doi: 10.23736/S0026-4946.16.04368-1.
17. Manini M.B., Matsunaga N.Y., Gianfrancesco L., Oliveira M.S., Carvalho M.R.V., Ribeiro G.L.M.T., Morais E.O., Ribeiro M.A., Morcillo A..M, Ribeiro J.D., Toro A.A. Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab. J Bras Pneumol. 2021. 47(5). e20210157. doi: 10.36416/1806-3756/e20210157.
18. Hammitt L.L., Dagan R., Yuan Y., Baca Cots M., Bosheva M., Madhi S.A., Muller W.J., Zar H.J., Brooks D.., Grenham A, Wählby Hamrén U., Mankad V.S., Ren P., Takas T., Abram M.E., Leach A., Griffin M.P., Villafana T.; MELODY Study Group. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med. 2022. 386(9). 837-846. doi: 10.1056/NEJMoa2110275. PMID: 35235726.
19. Griffin M.P., Yuan Y., Takas T.., Domachowske J.B., Madhi S.A., Manzoni P., Simões E.A.F., Esser M.T., Khan A.A., Dubovsky F., Villafana T., DeVincenzo J.P.; Nirsevimab Study Group. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020. 383(5). 415-425. doi: 10.1056/NEJMoa1913556.
20. Esposito S., Abu Raya B., Baraldi E., Flanagan K., Martinon Torres F., Tsolia M., Zielen S. RSV Prevention in All Infants: Which Is the Most Preferable Strategy? Front Immunol. 2022. 13. 880368. doi: 10.3389/fimmu.2022.880368.
21. Sanders S.L., Agwan S., Hassan M, van Driel M.L., Del Mar C.B. Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection. Cochrane Database Syst Rev. 2019. 8(8). CD009417. doi: 10.1002/14651858.CD009417.pub2.
22. Jacobino S.R., Nederend M., Reijneveld J.F., Augustijn D., Jansen J.H.M., Meeldijk J., Reiding K.R., Wuhrer M., Coenjaerts F.E.J., Hack C.E., Bont L.J., Leusen J.H.W. Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo. MAbs. 2018. 10(3). 453-462. doi: 10.1080/19420862.2018.1433974.
23. Zhou Y., Tong L., Li M., Wang Y., Li L., Yang D., Zhang Y. Recurrent Shortness of Breath and Asthma After Respiratory Syncytial Viral Bronchiolitis. Front Pediatr. 2021. 9. 649003. doi: 10.3389/fped.2021.649003.
24. Kitsantas P., Nirmalraj L. Effects of Respiratory Syncytial Virus Infection in Infancy on Asthma and Respiratory Allergy in 6-Year-Old Children. 2018. 111(11). 698-702. doi: 10.14423/SMJ.0000000000000881.
25. Krilov L.R., Roberts N.J. Jr. Respiratory Syncytial Virus (RSV) Update. Viruses. 2022. 14(10). 2110. doi: 10.3390/v14102110.
26. Mejias A., Wu B., Tandon N., Chow W., Varma R., Franco E, Ramilo O. Risk of childhood wheeze and asthma after respiratory syncytial virus infection in full-term infants. Pediatr Allergy Immunol. 2020. 31(1). 47-56. doi: 10.1111/pai.13131. Epub 2019 Oct 23
27. Coutts J., Fullarton J., Morris C., Grubb E.B., Buchan S., Gray B.R., Thwaites R. Association between respiratory syncytial virus hospitalization in infancy and childhood asthma. Pediatr Pulmonol. 2020. 55(5). 1104-1110. doi: 10.1002/ppul.24676. Epub 2020 Feb 10.
28. Heinonen S., Rodriguez-Fernandez R., Diaz A, Rodriguez-Pastor S.O., Ramilo O, Mejias A. Infant Immune Response to Respiratory Viral Infections. Immunol Allergy Clin North Am. 2019. 39(3). 361-376. doi: 10.1016/j.iac.2019.03.005. Epub 2019 May 15
29. Altman M.C., Reeves S.R., Parker A.R., Whalen E., Misura K.M., Barrow K.A., James R.G., Hallstrand T.S., Ziegler S.F., Debley J.S. Interferon response to respiratory syncytial virus by bronchial epithelium from children with asthma is inversely correlated with pulmonary function. J Allergy Clin Immunol. 2018. 142(2). 451-459. doi: 10.1016/j.jaci.2017.10.004.
30. Porto B.N., Litvack M.L., Cen Y., Lok I., Bouch S., Norris M.J., Duan W., Ackerley C., Post M., Moraes T.J. Alveolar-like Macrophages Attenuate Respiratory Syncytial Virus Infection. 2021. 13(10). 1960. doi: 10.3390/v13101960.
31. San-Juan-Vergara H., Peeples M.E. Importance of Virus Characteristics in Respiratory Syncytial Virus-Induced Disease. Immunol Allergy Clin North Am. 2019. 39(3). 321-334. doi: 10.1016/j.iac.2019.04.001.
32. Jadhao S.J., Ha B., Mc Cracken C., Gebretsadik T., Rosas-Salazar C., Chappell J., Das S., Hartert T., Anderson L.J. Performance evaluation of antibody tests for detecting infant respiratory syncytial virus infection. J Med Virol. 2021. 93(6). 3439-3445. doi: 10.1002/jmv.26736.
33. Homaira N., Briggs N., Pardy C., Hanly M., Oei J.L., Hilder L., Bajuk B., Lui K., Rawlinson W., Snelling T., Jaffe A. Association between respiratory syncytial viral disease and the subsequent risk of the first episode of severe asthma in different subgroups of high-risk Australian children: a whole-of-population-based cohort study. BMJ Open. 2017. 7(11). e017936. doi: 10.1136/bmjopen-2017-017936.
34. Priante E., Cavicchiolo M.E., Baraldi E. RSV infection and respiratory sequelae. Minerva Pediatr. 2018. 70(6). 623-633. doi: 10.23736/S0026-4946.18.05327-6.
35. Verwey C., Nunes M.C., Dangor Z., Madhi S.A. Pulmonary function sequelae after respiratory syncytial virus lower respiratory tract infection in children: A systematic review. Pediatr Pulmonol. 2020. 55(7). 1567-1583. doi: 10.1002/ppul.24804.
36. Dinwiddie D.L., Denson J.L., Kennedy J.L. Role of the Airway Microbiome in Respiratory Infections and Asthma in Children Pediatr Allergy Immunol Pulmonol. 2018. 31(4). 236-240. doi: 10.1089/ped.2018.0958. Epub 2018 Dec 12.
37. Fonseca W., Lukacs N.W., Ptaschinski C. Factors Affecting the Immunity to Respiratory Syncytial Virus: From Epigenetics to Microbiome. Front Immunol. 2018. 9. 226. doi: 10.3389/fimmu.2018.00226.
38. Harford T.J., Rezaee F., Gupta M.K., Bokun V., Naga Prasad S.V., Piedimonte G. Respiratory syncytial virus induces β 2-adrenergic receptor dysfunction in human airway smooth muscle cells. Sci Signal. 2021. 14(685). eabc1983. doi: 10.1126/scisignal.abc1983.
39. Zhang X., Zhang X., Zhang N., Wang X., Sun L., Chen N., Zhao S., He Q. Airway microbiome, host immune response and recurrent wheezing in infants with severe respiratory syncytial virus bronchiolitis. Pediatr Allergy Immunol. 2020. 31(3). 281-289. doi: 10.1111/pai.13183. Epub 2020 Jan 22.
40. Baraldi E., Bonadies L., Manzoni P. Evidence on the Link between Respiratory Syncytial Virus Infection in Early Life and Chronic Obstructive Lung Diseases. Am J Perinatol. 2020. 37(S 02). S26-S30. doi: 10.1055/s-0040-1714345.
Review
For citations:
Medvedeva A.S., Shcherbak V.A. THE RISK OF DEVELOPING ASTHMA IN CHILDREN, WHO HAVE HAD RESPIRATORY SYNCYTIAL INFECTION IN INFANCY. Transbaikalian Medical Bulletin. 2023;(2):141-150. (In Russ.) https://doi.org/10.52485/19986173_2023_2_141
Views:
82
Email this article 